Johnson & Johnson has agreed to pay $5.5 billion (roughly ₹52,700 crore) to settle tens of thousands of lawsuits linking its talc-based baby powder to cancer. The settlement, announced Wednesday, resolves claims from plaintiffs who allege the product caused ovarian cancer or mesothelioma. For Indian readers, this case highlights how global companies handle mass litigation, with potential ripple effects for consumer trust and corporate liability in emerging markets.
The lawsuits date back over a decade, with claimants arguing J&J knew its talc contained asbestos but failed to warn users. J&J has consistently denied the allegations, maintaining its products are safe. However, mounting legal costs and court losses pushed the company toward settlement. This is J&J's second attempt to resolve the cases; a previous $8.9 billion offer through a bankruptcy subsidiary was rejected by courts as improper.
Under the current plan, J&J will pay over 25 years, with the first payment of $2 billion expected within 12 months. The settlement covers about 99% of current lawsuits, but claimants must vote in favor. The company says it has set aside reserves and does not expect a major financial hit. Still, the payout is one of the largest product-liability settlements in history.
For affected families, the settlement provides compensation without years of court battles. But some critics argue the amount may be insufficient given the severity of the allegations. J&J shares rose slightly after the announcement, suggesting investor relief, though long-term reputational damage may persist.
Moving forward, the settlement still requires court approval and plaintiff acceptance. If successful, J&J will avoid a trial that could have revealed internal documents. The case serves as a reminder of the high stakes in consumer safety litigation and the global reach of corporate accountability. For Indian consumers, it underscores the importance of product regulation and transparency, especially for widely used household items.